Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

In Rae Cho

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9874-5526; OpenAlex author ID A5052238082, A5102242043. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 4 papers · 2023: none · 2024: 5 papers · 2025: 1 paper · 2026: 5 papers

Papers 21

  1. Lorazepam and Survival in Asian Patients with Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.1007/s12029-026-01429-7↗
  2. Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial. Co-author DOI 10.1016/j.ejca.2026.116903↗
  3. Characteristics of Pancreatic Cancer-associated Ascites and Redefined Criteria for Bacterial Peritonitis. First author DOI 10.1097/mpa.0000000000002606↗
  4. Treatment Outcomes in Frail Patients with Advanced Pancreatic Ductal Adenocarcinoma: A Real-World Comparison of Gemcitabine, S-1, and Stereotactic Ablative Rad… Co-author DOI 10.1159/000552276↗
  5. Ferroptosis-based therapeutic strategy targeting iron metabolism and SLC7A11 overcomes oxaliplatin resistance in patient-derived pancreatic cancer organoids. Co-author DOI 10.1186/s13046-026-03745-z↗
  6. ATR inhibition promotes synergistic antitumor effect in platinum-resistant pancreatic cancer. Co-author DOI 10.1016/j.bbadis.2024.167625↗
  7. Safety and Efficacy of Neoadjuvant SABR in Pancreatic Cancer: Effect of Magnetic Resonance Imaging-Guided Respiratory-Gated Adaptive Radiation Therapy. Co-author DOI 10.1016/j.adro.2023.101312↗
  8. Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX. First author DOI 10.1177/17588359241290482↗
  9. Enhanced Anti-tumor Effect of Flavopiridol in Combination With Gemcitabine in Pancreatic Cancer. First author DOI 10.21873/anticanres.16905↗
  10. Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib. Co-author DOI 10.3390/cancers16051056↗
  11. Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells. Co-author DOI 10.4062/biomolther.2023.109↗
  12. Accelerated Pancreatobiliary MRI for Pancreatic Cancer Surveillance in Patients With Pancreatic Cystic Neoplasms. Co-author DOI 10.1002/jmri.28189↗
  13. Cytokine-Induced Killer Cell Immunotherapy Combined With Gemcitabine Reduces Systemic Metastasis in Pancreatic Cancer: An Analysis Using Preclinical Adjuvant T… Co-author DOI 10.1097/mpa.0000000000002176↗
  14. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic a… Co-author DOI 10.1177/17588359221119539↗
  15. Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX. Co-author DOI 10.3389/fonc.2022.945829↗
  16. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103218↗
  17. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching … Co-author DOI 10.1186/s12885-021-08277-7↗
  18. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. Co-author DOI 10.4251/wjgo.v12.i2.182↗
  19. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A sing… Co-author DOI 10.1053/j.seminoncol.2018.01.001↗
  20. Clinical characteristics of second primary pancreatic cancer. First author DOI 10.1371/journal.pone.0179784↗
  21. Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.07.064↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sang Hyub Lee · 15 shared papers, 2021–2026 · strength 3.21
  2. Woo Hyun Paik · 14 shared papers, 2021–2026 · strength 3.16
  3. Ji Kon Ryu · 13 shared papers, 2021–2026 · strength 2.85
  4. Jin Ho Choi · 9 shared papers, 2022–2026 · strength 2.02
  5. Yong‐Tae Kim · 8 shared papers, 2021–2025 · strength 1.40
  6. Wooil Kwon · 3 shared papers, 2022–2026 · strength 0.66
  7. Huapyong Kang · 4 shared papers, 2017–2026 · strength 0.56
  8. Tae Seung Lee · 2 shared papers, 2024–2026 · strength 0.52
  9. Eui Kyu Chie · 2 shared papers, 2024–2026 · strength 0.49
  10. Jung Won Chun · 3 shared papers, 2021–2025 · strength 0.48
  11. Ja‐Lok Ku · 2 shared papers, 2024–2026 · strength 0.46
  12. Seung Woo Park · 5 shared papers, 2013–2021 · strength 0.37
  13. Si Young Song · 5 shared papers, 2013–2021 · strength 0.37
  14. Moon Jae Chung · 5 shared papers, 2013–2021 · strength 0.37
  15. Jeong Youp Park · 5 shared papers, 2013–2021 · strength 0.37
  16. Seungmin Bang · 5 shared papers, 2013–2021 · strength 0.37
  17. Woo Jin Lee · 2 shared papers, 2022–2025 · strength 0.35
  18. Sang Myung Woo · 2 shared papers, 2022–2025 · strength 0.35
  19. Hongbeom Kim · 2 shared papers, 2022–2024 · strength 0.34
  20. Jin‐Young Jang · 2 shared papers, 2022–2024 · strength 0.34
  21. Jung Hyun Jo · 4 shared papers, 2017–2021 · strength 0.34
  22. Hee Seung Lee · 4 shared papers, 2017–2021 · strength 0.34
  23. Tae Seung Lee · 1 shared paper, 2026 · strength 0.33
  24. Jin‐Young Jang · 1 shared paper, 2026 · strength 0.32
  25. Dong Ho Lee · 1 shared paper, 2026 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.